Moore Capital Management LP raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 198.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 599,860 shares of the biopharmaceutical company’s stock after purchasing an additional 399,111 shares during the quarter. Gilead Sciences accounts for 0.9% of Moore Capital Management LP’s portfolio, making the stock its 14th largest holding. Moore Capital Management LP’s holdings in Gilead Sciences were worth $37,005,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. HBK Sorce Advisory LLC boosted its holdings in shares of Gilead Sciences by 5.8% in the 3rd quarter. HBK Sorce Advisory LLC now owns 35,623 shares of the biopharmaceutical company’s stock worth $2,198,000 after acquiring an additional 1,965 shares in the last quarter. PFS Investments Inc. boosted its holdings in shares of Gilead Sciences by 36.2% in the 3rd quarter. PFS Investments Inc. now owns 484,653 shares of the biopharmaceutical company’s stock worth $29,898,000 after acquiring an additional 128,688 shares in the last quarter. MML Investors Services LLC boosted its holdings in shares of Gilead Sciences by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 213,648 shares of the biopharmaceutical company’s stock worth $13,180,000 after acquiring an additional 10,805 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of Gilead Sciences by 16.4% in the 3rd quarter. Nuveen Asset Management LLC now owns 7,991,520 shares of the biopharmaceutical company’s stock worth $492,997,000 after acquiring an additional 1,123,549 shares in the last quarter. Finally, Quantitative Investment Management LLC acquired a new position in Gilead Sciences during the 3rd quarter worth $1,879,000. 78.72% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Gilead Sciences news, insider Merdad Parsey sold 12,984 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $79.96, for a total transaction of $1,038,200.64. Following the completion of the transaction, the insider now owns 70,130 shares in the company, valued at approximately $5,607,594.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.
Gilead Sciences Price Performance
Gilead Sciences (NASDAQ:GILD – Get Rating) last released its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. The firm had revenue of $7.39 billion during the quarter, compared to analysts’ expectations of $6.63 billion. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. The company’s revenue was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.69 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 6.84 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Tuesday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.73. Gilead Sciences’s dividend payout ratio is 80.00%.
Analyst Ratings Changes
GILD has been the topic of several research reports. Morgan Stanley upped their price objective on Gilead Sciences from $80.00 to $81.00 and gave the stock an “equal weight” rating in a report on Friday, February 3rd. Oppenheimer upped their price objective on Gilead Sciences from $95.00 to $105.00 in a report on Thursday, December 1st. Cowen upped their price objective on Gilead Sciences from $90.00 to $95.00 in a report on Friday, February 10th. Robert W. Baird upped their price objective on Gilead Sciences from $69.00 to $80.00 in a report on Friday, February 3rd. Finally, Royal Bank of Canada reduced their price objective on Gilead Sciences from $87.00 to $86.00 and set a “sector perform” rating on the stock in a report on Monday. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.40.
Gilead Sciences Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey’s General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.